MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Sublocade$218M (33.74%↑ Y/Y)Sublingual And Other$50M (-7.41%↓ Y/Y)Perseris$5M (25.00%↑ Y/Y)US$272M (22.52%↑ Y/Y)Non Us$45M (2.27%↑ Y/Y)Net revenue$317M (19.17%↑ Y/Y)Gross profit$277M (25.34%↑ Y/Y)Cost of sales$40M (-9.09%↓ Y/Y)Operating income$137M (107.58%↑ Y/Y)Interest (income)$3M (-25.00%↓ Y/Y)Total operatingexpenses$139M (-10.90%↓ Y/Y)Income before incometaxes$115M (94.92%↑ Y/Y)Loss on debtextinguishment-$18M Interest expense$7M (-41.67%↓ Y/Y)Selling, general andadministrative$124M (-6.06%↓ Y/Y)Research and development$16M (-27.27%↓ Y/Y)Net income$89M (89.36%↑ Y/Y)Income tax expense$26M (136.36%↑ Y/Y)
Income Statement
indivior-logo-svg

Indivior Pharmaceuticals, Inc. (INDV)

indivior-logo-svg
source: myfinsight.com

Indivior Pharmaceuticals, Inc. (INDV)